Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
AlphaCentric LifeSci Healthcare Fund
LYFCX (Mutual Fund)
AlphaCentric LifeSci Healthcare Fund
Name
As of 10/07/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
4.5%
1 yr return
9.7%
3 Yr Avg Return
1.6%
5 Yr Avg Return
N/A
Net Assets
$104 M
Holdings in Top 10
41.2%
52 WEEK LOW AND HIGH
$13.3
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 2.66%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
$2,500
IRA
$2,500
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 10/07/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
LYFCX - Profile
Distributions
- YTD Total Return 4.5%
- 3 Yr Annualized Total Return 1.6%
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -2.21%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameAlphaCentric LifeSci Healthcare Fund
-
Fund Family NameMutual Fund Series Trust
-
Inception DateNov 29, 2019
-
Shares OutstandingN/A
-
Share ClassC
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerMark Charest
Fund Description
p id="xdx_A8C_err--StrategyNarrativeTextBlock_zEinqhTw0Q67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund seeks to achieve its investment objective by investing in the life sciences and healthcare related companies that the Fund’s investment sub-advisor, LifeSci Fund Management LLC (the “Sub-Advisor”), believes to have potential to appreciate in value. Under normal market conditions, the Fund invests at least 80% of its net assets plus borrowings for investment purposes in the securities of companies in the life sciences and healthcare sectorsi, /iwhich the Fund defines to be the category of companies related to producing or supplying facilities, supplies, technology, pharmaceuticals, equipment, devices or services for the preservation and care of a person’s or animal’s healthi. /iThe Fund invests in equity securities, primarily common stock, of these companies and may also invest, from time to time, in exchange traded funds (“ETFs”) that primarily invest in these companies. The Fund defines life sciences and healthcare companies to include those companies that are expected to derive 50% or more of their revenue from life sciences and healthcare related products and services. These companies may include development stage companies, which are entities span style="background-color: white"devoting substantially all of their efforts establishing a business for which commercial operations have not commenced or no significant revenue is being generated/span./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund may invest up to 15% of the Fund’s net assets in private and other companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid such as initial public offerings (“IPOs”), mezzanine financing offerings and other structured transactions. The Fund may invest in securities of companies of any market capitalization and in foreign companies either directly or through American Depositary Receipts (“ADRs”)./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund concentrates its investments (i.e., invests more than 25% of its assets) in the biotech and pharmaceutical; health care facilities and services; and medical equipment and devices industries, collectively. Each of these industries are commonly categorized within the healthcare sector because they share similar distribution channels and regulatory constraints./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"For hedging purposes or when the Sub-Advisor anticipates significant price changes due to company or market moving events, the Fund may also invest in inverse ETFs and purchase and sell call and put options on equity securities of life sciences and healthcare companies./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Sub-Advisor begins the investment selection process by systematically screening the universe of life sciences and healthcare companies using fundamental scientific and medical literature review, and input from leading scientific and medical experts to identify highly innovative thematic areas of interest. Financial analysis, market projections and corporate diligence are then performed to select the Fund’s investments./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund actively trades its portfolio investments, which may lead to higher transaction costs that may affect the Fund’s performance./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p
Read More
LYFCX - Performance
Return Ranking - Trailing
| Period | LYFCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 4.5% | -24.2% | 25.2% | 86.16% |
| 1 Yr | 9.7% | -5.4% | 42.3% | 92.45% |
| 3 Yr | 1.6%* | -30.2% | 13.6% | 56.58% |
| 5 Yr | N/A* | -2.8% | 15.8% | N/A |
| 10 Yr | N/A* | -0.7% | 13.3% | N/A |
* Annualized
Return Ranking - Calendar
| Period | LYFCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 3.3% | -12.6% | 19.0% | 44.03% |
| 2022 | -6.2% | -53.9% | 3.2% | 14.47% |
| 2021 | -15.0% | -39.6% | 24.2% | 78.29% |
| 2020 | 50.8% | -13.6% | 178.2% | 6.04% |
| 2019 | N/A | 3.8% | 63.8% | N/A |
Total Return Ranking - Trailing
| Period | LYFCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 4.5% | -24.2% | 25.2% | 86.16% |
| 1 Yr | 9.7% | -5.4% | 42.3% | 92.45% |
| 3 Yr | 1.6%* | -30.2% | 13.6% | 56.58% |
| 5 Yr | N/A* | -2.8% | 15.8% | N/A |
| 10 Yr | N/A* | -0.7% | 13.3% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | LYFCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 6.1% | -12.6% | 19.0% | 30.82% |
| 2022 | -1.8% | -53.9% | 3.7% | 10.53% |
| 2021 | -4.3% | -33.9% | 26.0% | 86.84% |
| 2020 | 54.3% | -0.7% | 180.6% | 4.70% |
| 2019 | N/A | 4.6% | 63.8% | N/A |
NAV & Total Return History
LYFCX - Holdings
Concentration Analysis
| LYFCX | Category Low | Category High | LYFCX % Rank | |
|---|---|---|---|---|
| Net Assets | 104 M | 6.87 M | 47.2 B | 77.36% |
| Number of Holdings | 60 | 26 | 414 | 73.58% |
| Net Assets in Top 10 | 34.1 M | 2.12 M | 22.1 B | 78.62% |
| Weighting of Top 10 | 41.22% | 18.4% | 79.7% | 78.62% |
Top 10 Holdings
- UNITED THERAPEUT 5.58%
- FIRST AM-TR OB-X 5.13%
- BIOCRYST PHARM 5.04%
- PFIZER INC 4.73%
- HARMONY BIOSCIE 4.44%
- PACIRA BIOSCIENC 4.06%
- ARGENX SE - ADR 3.76%
- GALAPAGOS NV-ADR 3.25%
- MIRUM PHARMACEUT 2.64%
- BEIGENE LTD-ADR 2.58%
Asset Allocation
| Weighting | Return Low | Return High | LYFCX % Rank | |
|---|---|---|---|---|
| Stocks | 94.77% | 87.34% | 106.13% | 85.53% |
| Cash | 5.23% | 0.00% | 32.72% | 17.61% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 39.62% |
| Other | 0.00% | -22.99% | 23.61% | 49.06% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 20.78% |
| Bonds | 0.00% | 0.00% | 12.39% | 35.22% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | LYFCX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 12.34% |
| Utilities | 0.00% | 0.00% | 0.00% | 16.88% |
| Technology | 0.00% | 0.00% | 22.69% | 24.03% |
| Real Estate | 0.00% | 0.00% | 5.89% | 20.78% |
| Industrials | 0.00% | 0.00% | 7.02% | 22.73% |
| Financial Services | 0.00% | 0.00% | 1.60% | 41.56% |
| Energy | 0.00% | 0.00% | 0.00% | 16.88% |
| Communication Services | 0.00% | 0.00% | 9.11% | 20.13% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 25.97% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 22.73% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 46.75% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | LYFCX % Rank | |
|---|---|---|---|---|
| US | 94.77% | 66.06% | 104.41% | 48.43% |
| Non US | 0.00% | 0.00% | 28.87% | 66.67% |
LYFCX - Expenses
Operational Fees
| LYFCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 2.66% | 0.08% | 4.48% | 10.69% |
| Management Fee | 1.25% | 0.03% | 1.25% | 96.86% |
| 12b-1 Fee | 1.00% | 0.00% | 1.00% | 79.22% |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| LYFCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| LYFCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| LYFCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | N/A | 0.00% | 238.00% | 96.91% |
LYFCX - Distributions
Dividend Yield Analysis
| LYFCX | Category Low | Category High | LYFCX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 11.95% |
Dividend Distribution Analysis
| LYFCX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
| LYFCX | Category Low | Category High | LYFCX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -2.21% | -2.54% | 1.85% | 98.68% |
Capital Gain Distribution Analysis
| LYFCX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 14, 2023 | $0.340 | CapitalGainShortTerm |
| Dec 15, 2022 | $0.549 | CapitalGainLongTerm |
| Dec 16, 2021 | $1.517 | CapitalGainShortTerm |
| Dec 16, 2021 | $0.061 | CapitalGainLongTerm |
| Dec 17, 2020 | $0.351 | OrdinaryDividend |
LYFCX - Fund Manager Analysis
Managers
Mark Charest
Start Date
Tenure
Tenure Rank
Nov 29, 2019
2.5
2.5%
Dr. Charest has served as a portfolio manager of LifeSci Fund Management since 2019. In 2017, he founded Phenomic Capital LLC to provide investment advice and consulting services focused on the healthcare sector. In 2019 Phenomic Capital became an affiliated majority owner of the LifeSci Fund Management. From 2015 to 2016, Mark was SVP at Tekla Capital Management, focused on public and private healthcare technology investments. Between 2012 and 2015, he was Portfolio Manager at New Leaf Venture Partners, focused on public healthcare technology investments. From 2010 to 2012, Dr. Charest was a Kauffman Fellow at Panorama Capital where he served on the board of directors of Itero Biopharmaceuticals and was a board observer at Presidio Pharmaceuticals and PowerVision. Dr. Charest is an inventor on eight drug patents. Prior to his investment career, he held an operating role in the oncology area as a Medicinal Chemistry Lab Manager at the Novartis Institutes for BioMedical Research. Dr. Charest earned his PhD in chemistry and chemical biology from Harvard University as a National Science Foundation Graduate Research Fellow, his MS in chemistry and chemical biology from Harvard University, and his BA in chemistry, with Highest Honors, from Rutgers University.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 22.1 |
